November 3, 2015
Sanofi and BioNTech Announce Cancer Immunotherapy Collaboration and License Agreement
Sanofi and BioNTech A.G. have entered into a multiyear exclusive collaboration and license agreement.
Pharmaceuticals, Biotechnology and Life Sciences
Tag: Sanofi
October 8, 2015
Sanofi and Genzyme:positive investigational data from the extension study of Lemtrada
Sanofi and its subsidiary Genzyme announced positive new five-year investigational data from the extension study of Lemtrada (alemtuzumab) for patients with relapsing remitting multiple sclerosis (RRMS).
October 7, 2015
Sanofi: New Analysis on Relapsing Multiple Sclerosis
Sanofi and its subsidiary Genzyme announced have that magnetic resonance imaging (MRI) data from the Phase III TEMSO study demonstrate that Aubagio (teriflunomide) significantly slowed brain volume loss (or atrophy) vs. placebo over two years in people with relapsing multiple sclerosis (RMS).
October 7, 2015
AstraZeneca Completes Divestment of Rare Disease Medicine Caprelsa
AstraZeneca has announced the global completion of the divestment of Caprelsa (vandetanib), a rare disease medicine, to Genzyme, a Sanofi company.
October 2, 2015
Sanofi: Genzyme Opts into Alnylam’s ALN-AT3 Hemophilia Program
Sanofi and its subsidiary Genzyme have announced that Genzyme has elected to opt into Alnylam’s investigational ALN-AT3 hemophilia program for development and potential future commercialization in territories outside of North America and Western Europe.
September 30, 2015
Sanofi: FDA to review New Drug Application for Lixisenatide
Sanofi announced on Tuesday that the U.S. Food and Drug Administration (FDA) has accepted for filing the New Drug Application (NDA) for lixisenatide.
September 28, 2015
Sanofi and Lilly end lawsuit and discontinue similar disputes worldwide
Eli Lilly has entered into a settlement agreement to resolve patent litigation with Sanofi regarding its insulin glargine product, Basaglar.